Salarius Pharmaceuticals, Inc. - SLRX STOCK NEWS

Salarius Pharmaceuticals (NASDAQ: SLRX) announced promising preclinical data on its targeted protein degrader SP-3164 for non-Hodgkin’s lymphomas (NHL). The data demonstrated synergistic effects with rituximab, achieving complete tumor elimination in 50% of treated mice, and superior efficacy compared to standard treatments. The company plans to submit an Investigational New Drug (IND) application for SP-3164 to the FDA and initiate a Phase 1 trial later in 2023. SP-3164, an oral small molecule, utilizes a unique platform to enhance treatment efficacy.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced that Dr. Aundrietta Duncan will present preclinical data on SP-3164 at the Molecular Glue Drug Development Summit from January 24-26, 2023. SP-3164, an oral next-generation molecular glue, aims to stabilize the preferred enantiomer of avadomide, showing promising efficacy in non-Hodgkin's lymphomas. The company plans to submit an Investigational New Drug application and initiate a Phase 1 trial in 2023. SP-3164 has received a composition of matter patent, and previous data indicated strong activity in lymphoma models. The CEO highlighted the importance of molecular glue degraders in targeting previously undruggable proteins.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced the issuance of U.S. Patent No. 11,535,603, protecting its second novel molecular glue, SP-3204, which targets disease-causing proteins for degradation. This expands Salarius' intellectual property portfolio to 16 issued patents across six families, enhancing their targeted protein degradation (TPD) platform. The patent covers SP-3204 through September 2037 and validates the company's commitment to protecting innovative therapies for cancers in need of new treatment options.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) announced promising results from an investigator-initiated Phase 1/2 study of seclidemstat combined with azacitidine for patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The study showed a 50% overall response rate among evaluable patients, with no serious adverse events reported. However, enrollment was paused in October due to a suspected unexpected serious adverse reaction in another study. Seclidemstat is being explored as a potential treatment for patients with limited options and has received various FDA designations.

Salarius Pharmaceuticals (NASDAQ: SLRX) presented promising preclinical data for SP-3164, a novel cancer therapy, at the 64th American Society of Hematology Annual Meeting. The data indicates that SP-3164 outperformed lenalidomide in DLBCL models and showed synergistic effects with rituximab, leading to complete tumor regressions in 50% of treated mice. Salarius plans to submit an Investigational New Drug application and initiate a Phase 1 trial for SP-3164 in 2023, aiming to enter a $16 billion market for molecular glues.

Salarius Pharmaceuticals (NASDAQ: SLRX) will hold a conference call on December 14, 2022, at 11:00 a.m. Eastern Time to discuss recent clinical data from its lead programs. Management will cover interim results from the ongoing Phase 1/2 trial of seclidemstat for Ewing sarcoma and FET-rearranged sarcomas. Additionally, new clinical data from MD Anderson's study involving seclidemstat will be highlighted, along with preclinical data on the targeted protein degrader SP-3164. Slides for the call will be accessible via the company’s website.

Salarius Pharmaceuticals (NASDAQ: SLRX) disclosed interim results from its Phase 1/2 trial of seclidemstat for Ewing sarcoma. The trial reported a 60% confirmed disease control rate in first-relapse patients, with a median time to tumor progression of 7.4 months. Interim results indicate that patients showed increased tumor progression time when treated with seclidemstat alongside standard chemotherapy. However, the trial is currently on partial clinical hold due to a serious adverse reaction, pending further review by the FDA. Salarius plans to resume patient enrollment following this review.

Salarius Pharmaceuticals (Nasdaq: SLRX) reported financial results for Q3 2022, highlighting a net loss of $14.4 million ($6.41 per share) compared to $3.7 million ($2.09 per share) in Q3 2021. Cash and cash equivalents fell to $16.8 million from $29.2 million at year-end 2021. The company noted progress on SP-3164, with plans to file an IND application in H1 2023. Recent presentations at industry conferences indicate promising preclinical data. However, a partial clinical hold on the seclidemstat trial due to adverse reactions raises concerns about future enrollment.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced the acceptance of two abstracts for presentation at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. One focuses on the preclinical compound SP-3164, showing potential therapeutic properties against lymphoma, while the second details a Phase I/II study of seclidemstat and azacitidine for myelodysplastic syndromes and chronic myelomonocytic leukemia, suggesting safety and potential activity. The presentations occur on December 12, 2022, at the Ernest N. Morial Convention Center, New Orleans.